Influence of biological sex, age and smoking on Graves’ orbitopathy – a ten-year tertiary referral center analysis

Influence of biological sex, age and smoking on Graves’ orbitopathy – a ten-year tertiary referral center analysis

PurposeSeverity of Graves’ orbitopathy (GO) shows wide individual differences. For optimal treatment, it is important to be able to predict the natural course of the disease as accurate as possible to counteract with anti-inflammatory and surgical treatment. Therefore, we aimed to further elucidate...

Full description

Bibliographic Details
Main Authors:	Michael Oeverhaus, Luisa Winkler, Kerstin Stähr, Anke Daser, Nikolaos Bechrakis, Mareile Stöhr, Ying Chen, Anja Eckstein
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-04-01
Series:	Frontiers in Endocrinology
Subjects:	Graves’ disease Graves’ orbitopathy thyroid eye disease (TED) TED GO RAI (radioiodine) ablation
Online Access:	https://www.frontiersin.org/articles/10.3389/fendo.2023.1160172/full

Similar Items

How Age Affects Graves’ Orbitopathy—A Tertiary Center Study
by: Michael Oeverhaus, et al.
Published: (2024-01-01)

Thyroid eye disease or Graves’ orbitopathy: What name to use, and why it matters
by: Lilly H. Wagner, et al.
Published: (2022-11-01)

Editorial: News in Graves’ orbitopathy: patients management and treatments
by: Giulia Lanzolla, et al.
Published: (2023-08-01)

High IgG4 serum concentration is associated with active Graves orbitopathy
by: Michał Olejarz, et al.
Published: (2023-03-01)

Life-threatening complications of high doses of intravenous methylprednisolone for treatment of Graves’ orbitopathy
by: Dorota Walasik-Szemplińska, et al.
Published: (2019-12-01)

Epidemiology, Natural History, Risk Factors, and Prevention of Graves’ Orbitopathy
by: Luigi Bartalena, et al.
Published: (2020-11-01)

Update on the surgical management of Graves’ orbitopathy
by: Joonyoung Baeg, et al.
Published: (2023-02-01)

Rituximab in the treatment of Graves’ orbitopathy: latest updates and perspectives
by: Jakub Supronik, et al.
Published: (2022-11-01)

Significance of thyroperoxidase and thyroglobulin antibodies in medically treated Graves’ disease
by: Stefan Matei Constantinescu, et al.
Published: (2023-12-01)

Steroid-resistant Graves' orbitopathy: Therapeutic options
by: Klet Sanja, et al.
Published: (2023-01-01)

Factors associated with severity of orbitopathy in patients with Graves' disease
by: Tauseef Nabi, et al.
Published: (2020-01-01)

Is Estrogen a Missing Culprit in Thyroid Eye Disease? Sex Steroid Hormone Homeostasis Is Key to Other Fibrogenic Autoimmune Diseases – Why Not This One?
by: Amy M. FitzPatrick
Published: (2022-06-01)

Evaluation of Quality of Life in the Brazilian Graves' Disease Population: Focus on Mild and Moderate Graves' Orbitopathy Patients
by: Danilo Villagelin, et al.
Published: (2019-04-01)

Current Knowledge on Graves’ Orbitopathy
by: Katarzyna Gontarz-Nowak, et al.
Published: (2020-12-01)

Modulating gut microbiota in a mouse model of Graves’ orbitopathy and its impact on induced disease
by: Sajad Moshkelgosha, et al.
Published: (2021-02-01)

Adipocytokines in Graves’ orbitopathy and the effect of high-dose corticosteroids
by: Jan Schovanek, et al.
Published: (2021-01-01)

Rituximab Treatment in a Patient with Active Graves’ Orbitopathy and Psoriasis
by: Tülay Şimşek, et al.
Published: (2017-01-01)

Puls-therapy with metilprednisolon in Grave's orbitopathy
Published: (2012-12-01)

Graves’ orbitopathy as a rare disease in Europe: a European Group on Graves’ Orbitopathy (EUGOGO) position statement
by: P. Perros, et al.
Published: (2017-04-01)

Not All Orbitopathy Is Graves’: Discussion of Cases and Review of Literature
by: Neeraja Boddu, et al.
Published: (2017-07-01)

Duration of antithyroid drug treatment may predict weight gain after radioactive iodine therapy in patients with Graves’ disease
by: Thewjitcharoen Yotsapon, et al.
Published: (2022-05-01)

Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves’ Orbitopathy
by: Irene Campi, et al.
Published: (2022-01-01)

Psychiatric complications in Graves’ disease
by: Mats Holmberg, et al.
Published: (2024-02-01)

Antithymocyte Globulin as Second-Line Therapy in Graves Orbitopathy—Preliminary Results From a Prospective Single-Center Study
by: Monika Sarnat-Kucharczyk, et al.
Published: (2022-05-01)

The change in the clinical presentation of Graves’ disease: a 30 years retrospective survey in an academic Brazilian tertiary center
by: Wanesa Pinto, et al.
Published: (2020-06-01)

Thyroid Receptor Antibody and the Development of Graves’ Orbitopathy: Clinical Experience of using Radioiodine Ablation in the Management of Graves’ Orbitopathy in post-iodine ablation hypothyroid patient
by: Edelyn Christina, et al.
Published: (2023-06-01)

TSH-receptor antibodies may prevent bone loss in pre- and postmenopausal women with Graves' disease and Graves' orbitopathy
by: Mira Siderova, et al.

Linsitinib, an IGF-1R inhibitor, attenuates disease development and progression in a model of thyroid eye disease
by: Anne Gulbins, et al.
Published: (2023-06-01)

Significance of HLA in Graves’ disease and Graves’ orbitopathy in Asian and Caucasian populations – a systematic review
by: Magdalena Stasiak, et al.
Published: (2023-09-01)

Risk factors for thyroid-associated orbitopathy due to Graves' disease
by: Tauseef Nabi, et al.
Published: (2021-01-01)

Tocilizumab as a steroid sparing agent for the treatment of Graves' orbitopathy
by: David J. Russell, et al.
Published: (2017-09-01)

Gut microbiota in experimental murine model of Graves’ orbitopathy established in different environments may modulate clinical presentation of disease
by: Giulia Masetti, et al.
Published: (2018-05-01)

Exophthalmos in a young woman with no Graves’ disease – a case report of IgG4-related orbitopathy
by: Annamaria Erdei, et al.
Published: (2018-01-01)

Antioxidant Therapy in Graves’ Orbitopathy
by: Giulia Lanzolla, et al.
Published: (2020-12-01)

Graves’ ophthalmopathy – thyroid eye disease
by: Dagna Siedlecka, et al.
Published: (2019-08-01)

Graves’ ophthalmopathy – thyroid eye disease
by: Dagna Siedlecka, et al.
Published: (2019-08-01)

Effects of Radioiodine Therapy on the Natural History of Graves' Ophtalmopathy
Published: (2007-09-01)

The association of race with thyroid eye disease presentation and outcomes
by: Diane Wang, et al.
Published: (2024-01-01)

Efficacy and safety of low dose oral prednisolone as compared to pulse intravenous methylprednisolone in managing moderate severe Graves′ orbitopathy: A randomized controlled trial
by: Ajitesh Roy, et al.
Published: (2015-01-01)

Associations between Lipid Profiles and Graves’ Orbitopathy can Be HLA-Dependent
by: Magdalena Stasiak, et al.
Published: (2023-05-01)